Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT007H in Recurrent/Refractory Pancreatic Cancer
NCT06478225Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- May 2024
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BGT007 in pancreatic cancer (PC), sponsored by Renji Hospital. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 3 years and 2 more. Started May 2024; status: recruiting.
02
Drugs
BGT007
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06478225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478225.